Skip to main content
. 2020 Nov 2;22:120. doi: 10.1186/s13058-020-01354-y

Table 2.

Best response by RECIST 1.1

Response No. of patients (%)
Confirmed CR 0 (0)
Confirmed PR 0 (0)
SD ≥ 4 months§ 6 (12)
SD < 4 months 11 (22)
Progressive disease 20 (40)
Non-evaluable* 13 (26)

CR complete response, PR partial response, SD stable disease

§One patient had an unconfirmed PR

*12 patients discontinued treatment before first post-baseline assessment due to clinical progression. One patient discontinued treatment before the first post-baseline assessment due to unacceptable toxicity